Plasma separation and adsorption for liver failure
Part of Digestive system, Infections clinical trials.
This trial tests a procedure that filters harmful substances from your blood using a special machine. It is for people with severe liver failure (acute-on-chronic) who have signs of inflammation throughout the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute-on-chronic liver failure with inflammation symptoms
- Your liver failure is at least grade II on the AARC scale
- You are not already on high-dose steroids for severe alcohol-related hepatitis
- You do not have liver cancer, a fungal infection, or severe bleeding problems
- You are not pregnant, on other trials, or have other major organ failure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether removing and replacing blood plasma (a blood-cleaning procedure) can help people with sudden, severe liver failure recover. The treatment aims to support the liver while it heals or while waiting for a transplant.
This study tests a blood-filtering system called CytoSorb in people with severe liver failure that also affects other organs. It aims to see if removing toxins from the blood can help reduce damage and improve recovery.
This trial tests a new liver dialysis device called DIALIVE 2.0 for people with acute-on-chronic liver failure (a sudden, severe worsening of chronic liver disease). If you qualify, the device will help filter your blood, similar to kidney dialysis, to support your liver while it tries to recover.
This trial is testing new scoring systems to better predict how patients with acute-on-chronic liver failure will do. It may help doctors make more informed treatment decisions for people with this serious liver condition.
This trial tests a device that uses a specially pig liver to help people with severe, sudden liver failure who cannot get a transplant. It aims to support the liver until it recovers or a transplant becomes possible.
This trial studies a treatment called the Double Plasma Molecular Adsorption System (DPMAS) for people with acute-on-chronic liver failure while they are in the ICU. It aims to see whether filtering certain substances from blood can improve outcomes and safety for critically ill patients.
Hear when a new Acute-on-Chronic Liver Failure (ACLF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.